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Antimicrobial Peptides  
and Suppression of Apoptosis  
in Human Skin
Michael Zasloff1
Antimicrobial peptides (AMPs) provide broad spectrum antimicrobial defense in 
both healthy and injured skin.  At high concentrations AMPs can damage normal 
human cells, resulting in necrosis or apoptotic death. In this issue Chammoro et al. 
(2009) describe a novel mechanism involving prostaglandin PGE2 that appears to 
explain how the keratinocyte, which secretes AMPs, can remain immune to self-
inflicted AMP-induced apoptosis.  
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microbial assault (Aberg et al., 2008). 
We also know that AMPs exhibit prop-
erties that would appear to help coordi-
nate the repair of a damaged epithelium. 
These include chemoattractant, growth 
stimulatory, and angiogenic activities 
(Gallo, 2008). We have learned that 
sunlight induces keratinocytes to pro-
duce cathelicidin (also called LL-37) via 
a vitamin D–mediated circuit, explain-
ing the efficacy of photo therapy in the 
treatment of cutaneous tuberculosis 
(Zasloff, 2006). In atopic dermatitis, epi-
dermal AMP expression is depressed, 
likely resulting from the inhibitory 
effects of atopic cytokines on the expres-
sion of several AMP genes, increasing 
the risk of secondary bacterial infections 
(Gallo, 2008). In contrast, in psoriasis 
a massive overexpression of numerous 
AMPs occurs, which helps explain the 
remarkable absence of infection in this 
condition despite the damaged skin 
(Harder and Schroder, 2005). In psoria-
sis, the overexpression of LL-37 has been 
suggested to play a role, in that cellular 
DNA, in complex with LL-37, appears 
to be an especially potent inducer of 
interferon-α by epidermal dendritic cells 
(Lande et al., 2007).
Most AMPs exert antimicrobial activ-
ities by damaging membranes in target 
organisms (Zasloff, 2002). AMPs, which 
are positively charged amphi pathic 
molecules, interact most avidly with 
membranes that expose anionic phos-
pholipid headgroups on the outer sur-
face of the bilayer, a design feature that 
characterizes many species of bacteria. 
In contrast, most cells that comprise 
multicellular animals are resistant to 
AMPs at their microbicidal concentra-
tions, because the anionic phospho-
lipids of these cells are segregated to 
the cytoplasmic surface of the plasma 
membrane and within the membranes 
of intracellular organelles, including the 
bacteria-like mitochondria.
However, at higher concentra-
tions, AMPs can damage eukaryotic 
cells because of their fundamental 
amphipathic design (Zasloff, 2002; 
Barlow et al., 2006). In some contexts, 
AMPs can physically disrupt the plasma 
membrane, creating “holes” of various 
dimensions and rapidly causing “necrot-
ic” cellular death. Alternatively, AMPs 
can induce apoptosis in certain cells 
at concentrations that do not destroy 
the plasma membrane (Barlow et al., 
2006). For example, the presence of 
AMP-specific receptors on the plasma 
membrane of a cell could encourage 
localized concentration of the peptide 
ligand within the membrane. If pep-
tides were then to transverse the plasma 
membrane and enter the cytoplasm, they 
would necessarily distribute to intra-
cellular sites with high surface concen-
trations of anionic phospholipids, such as 
mitochondria. As they do with microbes, 
AMPs can damage the integrity of 
Over the past several years, we have 
developed a picture of how endog-
enous antimicrobial peptides (AMPs) 
contribute to the health of human skin. 
We know that AMPs provide human 
epidermis with anti-infective defenses 
against bacteria, fungi, protozoa, and 
viruses (Zasloff, 2002). The major AMPs 
in human epidermis are synthesized by 
keratinocytes in the stratum granulosum, 
packaged along with complex lipids in 
lamellar bodies, and delivered into the 
stratum corneum, where they help to 
maintain a barrier against water loss and 
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mitochondria, a well-recognized trigger 
of apoptosis. Indeed, one of the key ini-
tiators of the apoptotic pathway, Bax, has 
been shown to perturb membranes very 
much like an AMP.
The storage and utilization within 
human epidermis of high concentra-
tions of membrane-active AMPs would 
seem to place proliferating keratino-
cytes at risk of damage from their own 
defensive products. Why are the pro-
liferating keratinocytes in psoriasis, for 
example, not destroyed by the high 
local concentrations of LL-37 peptide 
in microanatomical proximity? Does a 
mechanism of “AMP immunity” exist 
to protect the keratinocyte from AMP-
induced cell death?
Indeed, as reported by Chamorro et 
al. in this issue (2009), when human 
keratinocytes are exposed to LL-37, a 
novel circuit that suppresses apoptosis 
is triggered (see Figure 1). The reagent 
used to provoke apoptosis is camp-
tothecin, a topoisomerase I inhibitor. 
Pretreatment of normal human kerati-
nocytes with LL-37 protects them from 
camptothecin-induced apoptosis, evi-
denced by the LL-37-dependent acti-
vation of caspase 3. How does LL-37 
accomplish this? Through a “focused” 
expression analysis of genes involved in 
apoptosis, Chamorro et al. (2009) dis-
covered that cycoloxygenase-2 (COX2) 
and inhibitor of apoptosis protein 
(IAP-2) genes were upregulated follow-
ing exposure to LL-37. The induction of 
COX2 suggested that a prostaglandin 
might be involved in this antiapoptotic 
activity; indeed, LL-37 was shown to 
stimulate keratinocytes to secrete pros-
taglandin E2 (PGE2). Blocking produc-
tion of PGE2 with a selective COX-2 
inhibitor prevented LL-37 from pro-
tecting against camptothecin, suggest-
ing that PGE2 was a key mediator of 
LL-37’s antiapoptotic property. Indeed, 
in the absence of LL-37, exposure of 
normal human keratinocytes to PGE2 
caused the induction of IAP-2, prevent-
ing camptothecin-induced apoptosis. 
Thus, LL-37 protects keratinocytes by 
inducing COX2, which in turn gener-
ates PGE2; PGE2 then induces IAP-2, 
which inhibits caspase 3, breaking the 
apoptotic cascade.
Chamorro et al. (2009) did not 
explain the mechanism by which LL-37 
induces COX2 nor the mechanism by 
which PGE2 induced IAP-2. They also 
did not report whether the two known 
LL-37 receptors, FPRL1 and PX27, are 
involved in this antiapoptotic pathway.
A similar story has emerged regard-
ing another LL-37-producing cell, 
the human neutrophil. LL-37 protects 
human neutrophils from apoptosis 
through an interaction with its PX27 
receptor via an intracellular circuit that 
suppresses caspase 3. A role for pros-
taglandin has not been reported in this 
system (Barlow et al., 2006).
LL-37 is normally expressed at low 
levels in the keratinocytes of healthy, 
uninjured human skin. The LL-37 
gene is induced in human skin by UV 
radiation and by wound injury. In pso-
riasis, LL-37 is massively overexpressed 
in lesional skin through an unknown 
mechanism. Thus, it would be within 
these familiar contexts that the obser-
vations of Chamorro et al. (2009) 
regarding the antiapoptotic effects of 
LL-37 on the keratinocyte would play 
out. In the setting of UV irradiation, 
LL-37 would be expected both to pro-
vide antimicrobial defense to the dam-
aged barrier and to limit the extent of 
the “sunburn” through its antiapoptotic 
effect. In an epidermal wound, LL-37, 
expressed by keratinocytes and invad-
ing neutrophils to limit infection, could 
serve its antimicrobial function while 
simultaneously “shielding” proliferat-
ing keratinocytes from “friendly fire.”
The fundamental defect in psoriasis 
remains unknown. Keratinocyte apopto-
sis appears to be abnormally reduced in 
this condition, and several cytokines with 
antiapoptotic properties, such as IL-15, 
have been implicated to play a role (Raj 
et al., 2006). Chamorro et al. (2009) 
suggest that LL-37 could contribute to 
figure 1. An antiapoptotic defense induced in the human keratinocyte by LL-37. In the epidermis, 
LL-37 is induced following exposure to UV radiation and in the setting of injury. As a membrane-active 
cationic peptide, LL-37 can induce apoptosis; a hypothetical pathway potentially operative in the 
keratinocyte is presented. As described by Chamarro et al. (2009), LL-37 also induces a novel pathway in 
the keratinocyte that breaks the apoptotic circuitry: (1) LL-37 interacts with an as yet unidentified receptor 
on the keratinocytes; (2) expression of the COX2 gene is induced; (3) COX2 catalyzes the production of 
PGE2; (4) PGE2 interacts with its receptor and (5) induces the expression of the IAP-2 gene; and (6) IAP-2 
inhibits downstream caspases, suppressing apoptosis. The mechanism described by Chamarro et al. would 
permit the keratinocyte to survive in the midst of the high local concentrations of LL-37 that accumulate 
within human epidermis. IAP2, inhibitor of apoptosis protein 2; PGE2, prostaglandin E2.
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the state of decreased keratinocyte apop-
tosis that is observed in psoriasis.
Chamorro et al. (2009) predict 
that drugs that inhibit the synthesis of 
keratinocyte PGE2 could have adverse 
cutaneous side effects under condi-
tions where LL-37 would normally be 
induced. If LL-37 synthesis and release 
were not balanced by the synthesis of 
PGE2 in skin, LL-37 would be free to 
provoke apoptotic death in the prolif-
erating basal cells. Minor epidermal 
injury might lead to physical separa-
tion of the skin at the epidermal/dermal 
junction, with apoptosis of basal kera-
tinocytes, provoked by the induced 
LL-37. The resulting skin lesion might 
resemble toxic epidermal necrolysis 
(TEN) or the related milder state, 
Stevens–Johnson syndrome (SJS).
Indeed, TEN and SJS (along with more 
common skin reactions) are well-recog-
nized adverse events that occur within 
days to weeks following the administra-
tion of several nonsteroidal anti-inflam-
matory agents (NSAIDs), such as the 
oxicam NSAIDs (Mockenhaupt et al., 
2008). The mechanism responsible for 
NSAID-associated skin reactions has 
long been assumed to be a drug-pro-
voked sensitization in which cytotoxic 
T cells attack the keratinocyte layer; 
more recent studies have suggested 
that the process involves the activation 
of the FasL/Fas system in keratinocytes 
(Raj et al., 2006). How a drug activates 
the FasL/Fas system remains controver-
sial. However, active FasL is present in 
human epidermal keratinocytes, but 
localized within the cellular interior 
(Raj et al., 2006). Cellular “stress” or 
damage (such as that produced by UV 
radiation) is believed to cause FasL to 
flip to the surface and interact with 
Fas, provoking the apoptotic cascade. 
Does exposure of the keratinocytes to 
high concentrations of LL-37 perhaps 
normally “activate” FasL? The adminis-
tration of an NSAID would effectively 
neutralize the keratinocyte’s capacity 
to protect itself from LL-37-provoked 
apoptosis, resulting in an apparent 
adverse skin reaction characterized by 
keratinocyte death.
Does LL-37 play a role in the anti-
apoptotic phenotype of epidermal kera-
tinocytes in psoriasis, as proposed by 
Chamorro et al. (2009)? The literature 
suggests that both nonselective and 
COX2-specific NSAIDs do not gener-
ally improve skin lesions when used to 
treat psoriatic arthritis. Perhaps when 
the LL-37 receptor responsible for acti-
vation of COX2 expression is identified, 
an appropriate antagonist will be avail-
able to test this hypothesis in humans.
It remains to be seen whether this 
fascinating antiapoptotic property of 
LL-37, demonstrated in cell culture, 
actually plays out in human skin in vivo 
and how we can use this new informa-
tion to advance clinical practice.
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